Current Topics in Nonclinical Drug Development Series-

This third volume in the series focuses on such germane issues as the weight of evidence approach, the 3Rs, (Replacement, Reduction, and Refinement) personalized drug therapies, and oncology therapeutics, among others. Volumes in this series are aimed at toxicologists and toxicologic pathologists involved in drug development. This third volume in the series focuses on such germane issues as the weight of evidence approach, applying the 3Rs (replacement, reduction, and refinement), personalized drug therapies, and oncology therapeutics, among others. Volumes in this series are aimed at toxicologists, toxicologic pathologists, regulators, and study directors dealing with issues in study design, evaluation of findings, and presentation of data. In addition, the series will serve as an aid to academicians and graduate students studying nonclinical drug development. Key Features: Explores the critical issues and current topics important in nonclinical drug development Deals with day-to-day issues in study design, evaluation of findings, and presentation of data Aids academicians and graduate students pursuing research related to nonclinical drug development Delves into both the art and science of nonclinical drug development and its impact on translational medicine and human safety